Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Urocortin 3
Overview
Urocortin 3, also known as stresscopin, is a 38-amino acid peptide with high selectivity for CRF receptor 2. It produces vasodilation and increases cardiac contractility while exhibiting cardioprotective effects in models of cardiac stress and injury.
Mechanism of Action
The selective CRF2 receptor activation avoids hypothalamic-pituitary-adrenal axis stimulation, potentially offering a favorable profile for cardiovascular therapeutics.
Research Summary & Key Findings
Animal studies have shown that urocortin 3 improves hemodynamics and reduces infarct size in models of myocardial ischemia and heart failure. No clinical trial data in human cardiovascular disease have been published, and the peptide remains in preclinical investigation.
Clinical Status
Urocortin 3 is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.
Administration Routes
References
Primary literature
- PubMed: "Urocortin 3"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Urocortin 3"
Registered interventional and observational studies, including status and phase.
- PubChem: "Urocortin 3"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Cardiovascular
Eptifibatide (Integrilin)
FDA ApprovedA synthetic cyclic heptapeptide modeled after the KGD (Lys-Gly-Asp) disintegrin sequence found in the venom of the south...
View detailsNesiritide (Natrecor)
FDA ApprovedA recombinant form of human B-type natriuretic peptide (BNP), a 32-amino acid peptide naturally produced by ventricular ...
View detailsAngiotensin II (Giapreza)
FDA ApprovedA synthetic form of the endogenous octapeptide angiotensin II, the primary effector of the renin-angiotensin system. Ang...
View detailsSerelaxin (Relaxin-2)
InvestigationalSerelaxin is a recombinant form of human relaxin-2, a naturally occurring peptide hormone composed of two chains linked ...
View detailsNo lawful pathway today
Urocortin 3 is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so there is nothing for us to sell you here and no consultation to book. That can change: eight peptides moved back to a lawful pathway in February 2026.
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Join the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.